Comprehensive genomic profiling and prognostic analysis of cervical gastric-type mucinous adenocarcinoma

• Published in: Virchows Archiv : an international journal of pathology Vol. 479; no. 5; pp. 893 - 903
• Main Authors: Lu, Shanshan, Shi, Junping, Zhang, Xiaobo, Kong, Fangzhou, Liu, Lili, Dong, Xiaowei, Wang, Kai, Shen, Danhua
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2021; Springer Nature B.V
• Subjects: 1-Phosphatidylinositol 3-kinase; Adenocarcinoma; AKT protein; Cancer; Cell cycle; Cervical cancer; ErbB-2 protein; Genomics; Human papillomavirus; Lymph nodes; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Mutation; Next-generation sequencing; Original Article; p53 Protein; Pathogenesis; Pathology; Patients; Radiation therapy; Survival; Survival analysis; Target detection; Molecular targets; Genomic alterations; Next-generation sequencing; Prognosis; Cervix; Gastric-type mucinous adenocarcinoma
• ISSN: 0945-6317; 1432-2307
• DOI: 10.1007/s00428-021-03080-y

Gastric-type mucinous adenocarcinoma (GAS) is an uncommon cervical adenocarcinoma, which is not associated with human papillomavirus (HPV) infection. Compared with HPV-associated cervical adenocarcinoma, GAS has characteristics of larger volume, deep invasion, and easy to metastasize to distant sites. Also, GAS is typically resistant to chemo/radiotherapy. Few studies have reported the molecular genetic characteristics of GAS. In order to investigate the molecular genetic characteristics of GAS and reveal its possible pathogenesis, 15 GAS patients were enrolled from Peking University People’s Hospital (2009–2019) and examined with next-generation sequencing (NGS). Based on the clinicopathologic feature analysis, we found that the presence of lymph node metastasis and extensive lymphovascular invasion were associated with poor survival outcomes of GAS ( p = 0.0042 and p = 0.005, respectively). Based on the NGS testing, our results showed that the most frequently mutated gene was TP53 (8/15, 53.3%), followed by STK11 , CDKN2A , and ARID1A . STK11 mutations were more frequent in well-differentiated GAS (33.3% vs. 0.0%, p = 0.026) and patients with extensive lymphovascular invasion (33.3% vs. 0.0%, p = 0.044). Survival analysis revealed that STK11 mutations were significantly associated with the poor prognosis of GAS ( p = 0.01). Our results also showed that mutations in the target drug were detected in 53.3% of GAS patients. Patients with ERBB2 amplification (13.3%) presented the highest level of evidence according to OncoKB recommendations. These results indicate that the genomic alterations of GAS mainly involved the cell cycle and PI3K / AKT signaling pathways, and some therapeutic candidates were identified in GAS patients.